Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–164 of 164 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Seasonal Influenza vaccine Clear all

Conditions: Influenza
Interventions: Quadrivalent VLP Vaccine, Comparator TIV; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Anaheim, California • Miami, Florida • Lenexa, Kansas + 2 more

Conditions: Influenza
Interventions: FluLaval™ Quadrivalent, Fluzone® Quadrivalent; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 35 Months
Enrollment: 2,432 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 64
States / cities: Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 56 more

Conditions: Flu Vaccine
Interventions: Fluzone-High Dose Quadrivalent, Fluad, Flublock; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 65 Years to 125 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pregnancy Immune Function
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Inactivated H1N1 Vaccine, Trivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 531 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Atlanta, Georgia • Iowa City, Iowa • St Louis, Missouri + 4 more

Conditions: Influenza Vaccination
Interventions: Influenza vaccination; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Trivalent Influenza Vaccine; Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 40 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Influenza
Interventions: oseltamivir [Tamiflu]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Year to 12 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: West Palm Beach, Florida • Pittsburgh, Pennsylvania • Jackson, Tennessee + 1 more

Conditions: Influenza, Human
Interventions: MER4101, Inactivated Influenza Vaccine; Biological
Lead sponsor: Nova Immunotherapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: Seasonal Inactivated Influenza Vaccine; Biological
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions: Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine, Placebo; Biological
Lead sponsor: Medicago; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Hollywood, Florida • Miami, Florida

Conditions: Influenza, Human
Interventions: mRNA Seasonal Flu vaccine, Licensed Influenza Vaccine; Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years and older
Enrollment: 54,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 161
States / cities: Anniston, Alabama • Guntersville, Alabama • Glendale, Arizona + 128 more

Conditions: MELAS Syndrome
Interventions: Fluzone®; Biological
Lead sponsor: Stanford University; Other
Eligibility: 13 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Influenza
Interventions: Instramuscular vaccine; Biological
Lead sponsor: Medicago; Industry
Eligibility: 65 Years and older
Enrollment: 209 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 14
States / cities: Huntsville, Alabama • Chandler, Arizona • San Diego, California + 11 more

Conditions: Influenza, Human
Interventions: F2C22C/DL001Z, F2B22A/DL001Z, F2B22B/DL001Z, F2B22C/DL001Z, F2B22D/DL001Z, F2B22E/DL001Z, F2F22A/DL001Z, F2F22B/DL001Z, F2F22C/DL001Z, F2F22D/DL001Z, F2F22E/DL001Z, Control 1, F2F23D/DL001Z-NH, F2F23A/DL001Z-NH, F2F23B/DL001Z-NH, Control 2, F2F23C/DL001Z-NH, Control 3, F2F22F/DL001Z; Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 24
States / cities: Hialeah, Florida • Miami, Florida • Chicago, Illinois + 21 more

Conditions: Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host
Interventions: Bronchoscopy; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza A
Interventions: MHAA4549A, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 38
States / cities: Athens, Alabama • Costa Mesa, California • Fountain Valley, California + 32 more

Conditions: Influenza
Interventions: Vero cell-derived, trivalent, seasonal influenza vaccine, Placebo: Phosphate-buffered saline; Biological
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 7,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 36
States / cities: Tucson, Arizona • Sacramento, California • San Diego, California + 31 more

Conditions: Seasonal Influenza Vaccination
Interventions: Mailed influenza vaccination reminder notice; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 24 Months to 60 Months
Enrollment: 3,618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Influenza
Interventions: Live Attenuated Influenza Vaccine; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Decatur, Georgia

Search by objective public record fields.

Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

Senescent Immunity in Elders and Vaccine Responses (SILVER)

Assessment of Alterations in Immune Function During Pregnancy and Post Parturition

Sanofi Pasteur, TIV + H1N1, Pediatric Population

Study of Immune Responses to Influenza Vaccination

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)

Immune and Hormone Response to Influenza Vaccine

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults

A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age

Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)

Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2

A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults

Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection

Seasonal Influenza Vaccination Reminders for Children With High-risk Conditions

Revealing Protective Immunity to Influenza Using Systems Immunology